The 10-second takeaway
For the quarter ended Dec. 31 (Q4), DexCom beat expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP loss per share increased.
Margins expanded across the board.
DexCom tallied revenue of $22.4 million. The 16 analysts polled by S&P Capital IQ expected net sales of $21.6 million on the same basis. GAAP reported sales were 43% higher than the prior-year quarter's $15.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.18. The 15 earnings estimates compiled by S&P Capital IQ predicted -$0.17 per share. GAAP EPS were -$0.18 for Q4 against -$0.16 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 47.7%, 300 basis points better than the prior-year quarter. Operating margin was -54.8%, 840 basis points better than the prior-year quarter. Net margin was -54.6%, 820 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $20.2 million. On the bottom line, the average EPS estimate is -$0.19.
Next year's average estimate for revenue is $95.8 million. The average EPS estimate is -$0.62.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 83 members out of 180 rating the stock outperform, and 97 members rating it underperform. Among 79 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 31 give DexCom a green thumbs-up, and 48 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on DexCom is outperform, with an average price target of $11.54.
The healthcare investing landscape is littered with also-rans and a few major winners. Is DexCom the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add DexCom to My Watchlist.